To celebrate the 3rd World Flu Day
Date: 1st – 2nd November 2020
Location: Beijing Cenference Center, Beijing, China
The 2020 World Influenza Conference (WIC) was held on 1 to 2 November 2020 as an event with both online and on-site attendees. The theme of the Conference was “Influenza Control and COVID-19 Pandemic Response”. Stakeholders, scientific organizations, governmental agencies, research institutes around the world got together to discuss the approaches to promote influenza prevention and control during the COVID-19 pandemic while reducing the risk of co-infection with influenza and COVID-19 to further improve the overall influenza prevention and control capacity of China and strengthen academic exchanges among influenza prevention and control experts around the world.
The 2020WIC was co-hosted by the Chinese Preventive Medicine Association (CPMA), the Asia-Pacific Alliance for the Control of Influenza (APACI), China CDC and the Chinese Academy of Medical Sciences (CAMS), in collaboration with the European Scientific Working group on Influenza (ESWI), the National Adult and Influenza Immunization Summit (NAIIS) and the International Society for Influenza and other Respiratory Virus Diseases (isirv).
2020 World Influenza Conference recordingProgram
Day 1 – Sunday, 1st November 2020
Keynote addresses
Soumya Swaminathan, Chief Scientist, WHO.
Policy development for the distribution of SARS-CoV-2 vaccines: can we rely on experience from pandemic influenza vaccines?
Wang Chen, Academician of Chinese Academy of Engineering, President, Chinese Academy of Medical Sciences and Peking Union Medical College.
Knowledge on the control of influenza applied in the fight against COVID-19: honoring global health and scientific professional.
George Fu Gao, Academician of Chinese Academy of Sciences, Director General, China CDC.
Celebrating World Influenza Day for global partnership and raising awareness in the midst of COVID-19.
Session 1: New evidence in support: policy development
Alexander Millman (USA)
Updates on influenza global disease burden.
Joe Bresee (USA)
Integrating seasonal influenza control policy development and pandemic preparedness.
Raymond Hutubessy (WHO)
Importance of health economics in public health policy development for influenza control
Session 2: New evidence and technology in support: influenza vaccines
Arnold Monto (USA)
Influenza vaccine effectiveness estimates for out-patient medical consultation, hospitalization and mortality, and high risk population.
PresentationRaja Dhar (India)
Influenza vaccination in patients with chronic respiratory and cardiovascular diseases and diabetes.
Lance Rodwald (USA)
Maternal, healthy adult, childhood and the elderly influenza vaccination.
Feng Luzhao (China)
WHO and China’s influenza vaccination recommendations during the COVID-19 Pandemic.
Session 3: New evidence and technology in support: influenza therapeutic/prophylactic drug development
Fred Hayden (USA)
Advances in influenza antiviral treatment.
Wu Yiling (China)
New evidence to support the use of traditional medicine for the control of influenza.
Aeron Hurt (Switzerland)
Maternal, healthy adult, childhood and the elderly influenza vaccination.
Aeron Hurt (Switzerland)
New evidence in the use of antivirals to reduce the spread of influenza.
Tim Uyeki (USA)
Challenges in the clinical management of influenza.
Session 4: Research and innovation for influenza control
Kanta Subbarao (Australia)
Seasonal and pandemic influenza vaccines: principles and challenges.
Ben Cowling (China)
Application and effectiveness of next-generation vaccines for influenza control in specific patient groups.
Shu Yuelong (China)
Advances in the search for biomarkers with prognostic potentials for influenza disease management.
Li Chengjun (China)
Successful control of H7N9 influenza virus in China.
Program
Day 2 – Monday, 2nd November 2020
Session 1: Virology of SARS-CoV-2
Guo Deyin (China)
Classification and replication of coronaviruses.
Wang Jianwei (China)
Molecular evolution of SARS-CoV-2 virus and epidemiological significance.
Zhou Xi(China)
Pathogenesis and Biomarkers of COVID-19.
Session 2: Case definition and clinical presentation of SARSCoV-2 infection: similarities/differences with influenza
Jiang Rongmeng (China)
Spectrum of clinical presentation and manifestations associated with SARS-CoV-2.
David Hui (China)
Current approach for the treatment of severe SARS-CoV-2 infection.
Wu Anhua (China)
Challenges in infection control practices presented by SARS and COVID-19.
Session 3: Antiviral development, clinical management and nonpharmaceutical interventions for SARS-CoV-2 infection
Cao Bin
Clinical trials in COVID-19 therapies.
Zhang Yi (China)
Immunopathogenesis and immunotherapeutics in SARS-CoV-2 infection.
Ben Cowling (China)
Application and effectiveness of non-pharmaceutical interventions for COVID-19 and influenza control.
Session 4: Surveillance, epidemiology and disease burden of COVID-19 pandemic
Feng Zijian (China)
Global burden and risk groups for severe COVID-19 disease: comparison with influenza pandemics.
Cécile Viboud (USA)
Progress on the use of “Big Data” for the surveillance of COVID-19 and influenza pandemics.
PresentationMatthew Biggertaff(USA)
Mathematical modeling on COVID-19 pandemic progression.
Maria Van Kerkhove (WHO)
Update on the global epidemiology of COVID-19.
Zhang Wenqing (WHO)
Surveillance and diagnosis of COVID-19: would influenza surveillance network be of help?
Session 5: Vaccine development and application for the control of COVID-19
Jiang ShiBo (China)
Research and Development of Broad-spectrum Anti-coronavirus Vaccines.
Zhang Yuntao (China)
Update on SARS-CoV-2 vaccine development.
Beverley Taylor (UK)
Challenges in the global supply of COVID-19 vaccines: points of view of the pharmaceutical industry.
PresentationLitjen Tan (USA)
Innovative approach in the application of vaccines for the control of SARS-CoV-2 and influenza infections.